Producing Monoclonal Antibody Patents (Class 435/70.21)
  • Patent number: 10174109
    Abstract: The present invention relates to methods of making human anti-HMGB1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions in HMGB1 associated-neuropathy.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: January 8, 2019
    Inventors: Li-Te Chin, Shu-Ching Hsu, Kai-Chen Wang
  • Patent number: 9957329
    Abstract: This application relates to neurological inflammatory diseases, such as multiple sclerosis, and to methods of administering a Factor XII inhibitor to prevent, treat, or otherwise ameliorate the effects of a neurological inflammatory disease, such as multiple sclerosis. Agents and pharmaceutical compositions comprising agents which inhibit the activity of FXII are also provided.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: May 1, 2018
    Assignees: CSL Behring GmbH, CSL Ltd., Julius-Maximilians-Universitaet-Wuerzburg, Westfaelische Wilhelms-Universitaet Muenster
    Inventors: Sven Meuth, Kerstin Goebel, Christoph Kleinschnitz, Brent McKenzie, Marc Nolte
  • Patent number: 9840555
    Abstract: The present invention relates to methods of making human anti-HMGB1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions in HMGB1 associated-neuropathy.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: December 12, 2017
    Inventors: Li-Te Chin, Shu-Ching Hsu, Kai-Chen Wang
  • Patent number: 9770496
    Abstract: The invention relates to methods for treating human amyloid disease by administration of modified A? peptide immunogens.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: September 26, 2017
    Assignee: New York University
    Inventors: Thomas Wisniewski, Fernando Goni
  • Patent number: 9752128
    Abstract: The present invention relates to cellular differentiation and, in particular to hybrid cells that exhibit phenotypic plasticity and methods for producing these cells. The invention also relates to methods for generating specific cells of a desired phenotype. The invention still further relates to methods of producing hybrid cells with a capacity to de-differentiate into an earlier progenitor state. The invention further contemplates the use of hybrid cells in a range of applications, for example tissue generation.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: September 5, 2017
    Assignee: Stephen Sanig Research Institute Ltd.
    Inventors: Galina Kaseko, Tohsak L. Mahaworasilpa
  • Patent number: 9719996
    Abstract: The invention provides anti-mesothelin antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: August 1, 2017
    Assignee: GENENTECH, INC.
    Inventors: Mark Dennis, Suzanna J. Scales, Susan D. Spencer, Yin Zhang
  • Patent number: 9522184
    Abstract: The invention relates to the use of CD89 activating molecules, in particular Fc alpha comprising molecules, and more particularly, IgA, for inducing apoptosis in neutrophils. Anti-CD89 antibodies can alternatively be used. The CD89 activation is beneficial in the treatment of various disorders associated with increases in neutrophils, such as autoimmune disorders, inflammatory disorders, NETosis, or cystic fibrosis.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: December 20, 2016
    Assignees: CSL BEHRING AG, UNIVERSITAT BERN
    Inventors: Stephan Von Gunten, Marc Wehrli, Adrian Zürcher, Sylvia Miescher
  • Patent number: 9476880
    Abstract: Methods for detecting acute kidney injury in an individual comprise (a) contacting a body fluid sample from the individual with an assay device including neutrophil gelatinase-associated lipocalin (NGAL) antibody and a detectable label, to allow complexing of NGAL protein in the sample with NGAL antibody, and determining an amount of complex formed between NGAL protein from the sample and NGAL antibody in the assay device using the detectable label, wherein NGAL antibody in the device has binding capacity with more than two NGAL protein epitopes, and wherein the amount of the formed complex represents a level of acute kidney injury. Methods for determining an origin of NGAL protein in a sample from an individual include the step of determining relative amounts of monomeric, dimeric and heterodimeric forms of NGAL protein in the sample and allow improved diagnosis and therefore better targeted treatment.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: October 25, 2016
    Assignee: FUTURE MEDICAL DIAGNOSTICS CO., LTD.
    Inventor: Per Venge
  • Patent number: 9452206
    Abstract: The present invention includes a method and device for the isolation of lymphocytes, particularly splenic lymphocytes, for administration to patients. In particular for patients undergoing a splenectomy, administration of splenic lymphocytes may increase a patient's immunity and reduce the likelihood of post-splenectomy infections and other complications.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: September 27, 2016
    Assignee: CHILDREN'S HOSPITAL OF ORANGE COUNTY
    Inventor: Mustafa Kabeer
  • Patent number: 9365652
    Abstract: Reducing liver fibrosis in a subject having or being suspected of having a liver disease using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: June 14, 2016
    Assignee: National Cheng Kung University
    Inventor: Ming-Shi Chang
  • Publication number: 20150147784
    Abstract: Two universally conserved sequences from influenza type A neuraminidases were identified by large scale sequence analysis then chemically modified and conjugated to carrier proteins to generate mono-specific and monoclonal antibodies. The two antibodies, one targeting the N-terminus of the type A neuraminidase and the other sequence close to enzymatic active site, were capable of binding to all 9 subtypes of neuraminidase while demonstrating remarkable specificity against the viral neuraminidase sequences since no cross-reactivity against allantoic proteins was observed. Quantitative analyses of NA using slot blot suggest that the antibodies can be used for NA antigen quantitation in vaccines. These represent the first time the antibody-based immunoassay can be used for NA quantitative determination.
    Type: Application
    Filed: December 1, 2014
    Publication date: May 28, 2015
    Inventors: Xuguang Li, Runtao He, Gary Van Domselaar
  • Patent number: 9034330
    Abstract: A method of preparing an antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex comprises the steps of (a) preparing an antibody or antibody fragment; (b) mixing said antibody or antibody fragment with a cationic liposome to form a cationic immunoliposome or with a cationic polymer to form a polyplex; and (c) mixing said cationic immunoliposome or said polyplex with a therapeutic or diagnostic agent to form said antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: May 19, 2015
    Assignee: Georgetown University
    Inventors: Esther H. Chang, Kathleen F. Pirollo
  • Patent number: 9034329
    Abstract: The present invention provides methods of preparing an antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex comprising (a) preparing an antibody or antibody fragment; (b) mixing said antibody or antibody fragment with a cationic liposome to form a cationic immunoliposome or with a cationic polymer to form a polyplex; and (c) mixing said cationic immunoliposome or said polyplex with a therapeutic or diagnostic agent to form said antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex. The present invention also provides cationic immunoliposome or polymer complexes produced by such methods and compositions comprising such complexes. The present invention also provides methods for treating various diseases and disorders, including cancers, by administering the complexes and compositions of the invention to a patient.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: May 19, 2015
    Assignee: Georgetown University
    Inventors: Esther H. Chang, Kathleen F. Pirollo
  • Publication number: 20150132322
    Abstract: This invention provides a human antibody, a hybridoma cell line for the production of the antibody, a reconstituted mouse strain for the production of the hybridoma, and methods of producing and using thereof.
    Type: Application
    Filed: May 6, 2013
    Publication date: May 14, 2015
    Inventors: Jean Elie Kadouche, Alain Razafindrastita
  • Patent number: 9023621
    Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: May 5, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Alexandra L. L. Lazetic, Christopher J. Bond
  • Patent number: 9005924
    Abstract: The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: April 14, 2015
    Assignee: ESBATech
    Inventor: Dominik Escher
  • Patent number: 9005921
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: April 14, 2015
    Assignees: ZymoGenetics, Inc., Merck Serono S/A
    Inventors: Kent Bondensgaard, Roland Beckmann
  • Patent number: 8999324
    Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: April 7, 2015
    Assignee: Roche GlycArt AG
    Inventors: Pablo Umaña, Joël Jean-Mairet
  • Patent number: 8993261
    Abstract: The invention relates to antibodies that are capable to bind the extracellular domain of integrin. Another object of the invention concerns the use of said antibodies for detecting integrins in archival formalin fixed paraffin embedded (FFPE) tissue. The invention also relates to methods for preparing monoclonal rabbit antibodies, wherein the immunogen is an insect expression culture-derived recombinant extracellular integrin domain, and another method for screening anti-integrin antibodies that discriminate between closest integrin homologues and that are especially suited for immunohistochemistry in FFPE material.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: March 31, 2015
    Assignee: Merck Patent GmbH
    Inventors: Simon Goodman, Claudia Wilm, Francesc Mitjans
  • Patent number: 8993228
    Abstract: The present invention provides an antibody that specifically binds to envelope protein 2 of HCV of genotype 2a but does not immunologically react with envelope protein 2 of HCV of genotype 1a.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: March 31, 2015
    Assignees: Toray Industries, Inc., Japan as Represented by Director General of National Institute of Infectious Diseases
    Inventors: Takaji Wakita, Yuko Akazawa, Noriko Nakamura
  • Patent number: 8981071
    Abstract: This invention provides antibodies that interact with or bind to human B7 related protein-1 (B7RP1) and antibodies that bind to and neutralize the function of B7RP1 thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing B7RP1 function, and particularly for treating immune disorders (e.g., inappropriate immune response) by administering a pharmaceutically effective amount of anti-B7RP1 antibodies. Methods of detecting the amount of B7RP1 in a sample using anti-B7RP1 antibodies are also provided.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: March 17, 2015
    Assignees: Amgen, Inc., Medarex, L.L.C.
    Inventors: Gerald Siu, Wenyan Shen, Steven K. Yoshinaga, Haichun Huang
  • Patent number: 8975384
    Abstract: The present invention provides a tag peptide comprising an amino acid sequence represented by the following formula (I): X1-Tyr-X2-Gly-Gln-X3??(I) (wherein X1, X2 and X3 are the same or different and each represent any amino acid residue) and an antibody against the tag peptide. By combined use of the tag peptide and antibody of the present invention, a system that enables proteins expressed from cloned genes to be highly purified in an inexpensive and easy manner can be established.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: March 10, 2015
    Assignee: Osaka University
    Inventor: Junichi Takagi
  • Publication number: 20150065692
    Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
    Type: Application
    Filed: November 12, 2014
    Publication date: March 5, 2015
    Inventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
  • Patent number: 8968736
    Abstract: The present invention provides antibodies that bind to human GFR?3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GFR?3. The antibodies of the invention are useful for the treatment of diseases and disorders associated with one or more GFR?3 biological activities, including the treatment of acute or chronic pain conditions, or inflammatory conditions.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: March 3, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Susan D. Croll, Lynn Macdonald, Andrew J. Murphy
  • Patent number: 8969529
    Abstract: The invention is based on the discovery of the epitope in the Stx2 protein for the 11 E1O antibody. The invention features compositions containing non-full length Stx2 polypeptides that include the 11 E1O monoclonal antibody epitope. The invention also features methods of producing anti-Stx2 antibodies specific for the 11 E1O epitope of the Stx2 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 11 E1O epitope or with an anti-Stx2 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx2 in a sample using the antibodies developed using the methods of the invention.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: March 3, 2015
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Alison O'Brien, Angela Melton-Celsa, Michael Smith, James Sinclair
  • Patent number: 8969024
    Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: March 3, 2015
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Zehra Kaymakcalan, Limin Xiong
  • Patent number: 8956830
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using DMSO, are described.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 17, 2015
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Holly Prentice, Rasheed Tijani, Brett Belongia
  • Patent number: 8945547
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 3, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
  • Patent number: 8945857
    Abstract: The invention provides methods for isolating cells, particularly antibody-secreting cells that have a high likelihood of secreting antibodies specific for a desired antigen for the purpose of making monoclonal antibodies.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: February 3, 2015
    Inventor: John Schrader
  • Patent number: 8945867
    Abstract: The present invention relates to a process for producing a desired polypeptide using rat cells. Specifically, the present invention relates to a process for producing the polypeptide which comprises culturing rat cells such as YB2/3HL.P2.G11.16Ag.20 (hereinafter referred to as YB2/0), preferably rat cells to which a recombinant DNA comprising DNA encoding a desired polypeptide such as an immunologically functional molecule is introduced, in a medium which does not contain serum (hereinafter referred to as a serum-free medium). Among the desired polypeptides obtained by the process of the present invention, an antibody obtained by using a transformant of YB2/0 has a high antibody-dependent cell-mediated cytotoxic activity (hereinafter sometimes referred to as ADCC activity) and is useful as a pharmaceutical agent.
    Type: Grant
    Filed: February 2, 2009
    Date of Patent: February 3, 2015
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Tatsuya Ogawa, Yoshinobu Konno, Naohisa Akashi, Hiroshi Takasugi, Seiji Sugimoto, Keiichi Yano
  • Patent number: 8945870
    Abstract: An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as “ASCT2”) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of ASCT2 and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: February 3, 2015
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Norihiko Shiraishi, Akiko Furuya, Hiroe Toki, Hiroshi Ando, Masayo Suzuki, Tsuguo Kubota
  • Patent number: 8945873
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: February 3, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • Patent number: 8945874
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: February 3, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
  • Patent number: 8940963
    Abstract: Process of producing in a plant, in plant tissue, or in plant cells a hetero-oligomeric protein comprising at least a first and a second protein subunit, said process comprising expressing in plant cells at least said first and said second protein subunit by (i) providing to said plant, said plant tissue or said plant cells a plus-sense single-stranded RNA viral vector encoding at least said first and said second protein subunit or (ii) providing to said plant, said plant tissue or said plant cells a first and a second plus-sense single-stranded RNA viral vector, said first viral vector encoding at least said first protein subunit, said second viral vector encoding at least said second protein subunit, whereby at least said first viral vector and said second viral vector are non-competing viral vectors.
    Type: Grant
    Filed: January 27, 2006
    Date of Patent: January 27, 2015
    Assignee: Icon Genetics GmbH
    Inventors: Anatoly Giritch, Sylvestre Marillonnet, Victor Klimyuk, Yuri Gleba
  • Patent number: 8926982
    Abstract: Two universally conserved sequences from influenza type A neuraminidases were identified by large scale sequence analysis then chemically modified and conjugated to carrier proteins to generate mono-specific and monoclonal antibodies. The two antibodies, one targeting the N-terminus of the type A neuraminidase and the other sequence close to enzymatic active site, were capable of binding to all 9 subtypes of neuraminidase while demonstrating remarkable specificity against the viral neuraminidase sequences since no cross-reactivity against allantoic proteins was observed. Quantitative analyses of NA using slot blot suggest that the antibodies can be used for NA antigen quantitation in vaccines. These represent the first time the antibody-based immunoassay can be used for NA quantitative determination.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: January 6, 2015
    Inventors: Xuguang Li, Runtao He, Gary Van Domselaar
  • Publication number: 20140377262
    Abstract: Materials and methods are provided for treating influenza B infections in humans. Anti-human influenza virus monoclonal antibodies and antigen-binding fragments thereof having a neutralization activity against a human influenza B virus are provided. Methods for producing anti-human influenza B virus monoclonal antibodies are also provided. The antibodies and antigen-binding fragments thereof can be effective against a wide range of influenza B viral strains. Methods of inhibiting or treating a human influenza B infection are provided. The anti-influenza B therapeutics can also be used to manufacture medicaments effective against influenza B infections, to detect human influenza B in a human subject, for use in pharmaceutical compositions, and for use in kits for at least one of the prevention, the treatment, and the detection of human influenza B in a human subject.
    Type: Application
    Filed: January 31, 2013
    Publication date: December 25, 2014
    Applicants: OSAKA UNIVERSITY, THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY, MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD., DEPARTMENT OF MEDICAL SCIENCES
    Inventors: Mayo Yasugi, Motoki Kuhara, Jotika Boon-Long, Kazuhito Fujiyama, Ritsuko Koketsu, Kazuyoshi Ikuta
  • Patent number: 8916152
    Abstract: The invention relates to antibodies against S100A4, methods for the preparation of these antibodies, pharmaceutical compositions comprising these antibodies, and therapeutic and diagnostic uses thereof.
    Type: Grant
    Filed: June 14, 2011
    Date of Patent: December 23, 2014
    Assignee: Lykera Biomed SA
    Inventors: Jose Luis Hernandez Miguez, Jaume Adan Plana, Josep Maria Martinez Escola, Marc Masa Alvarez, Ramon Messeguer Peypoch, Francesc Mitjans Prat, Sheila Dakhel Plaza, Antonio Coll Manzano, Rosa Ma Hervas Villegas, Carme Calvis Calpe, Laura Padilla Garcia, Lourdes Tatiana Roque Navarro, Laura Barbera Ferrando, Manuel Rivas Canas, Luis Angel Gomez Casajus
  • Patent number: 8911731
    Abstract: The present invention provides monoclonal antibodies which specifically recognize the shorter A? peptides obtained after cleavage of the APP protein mediated by ?-secretase, i.e. the A?-peptide fragments A?1-37, A?3-37, A?3p-37, A?1-37 and A?11p-37, and other like fragments ending at the 37th amino acid of APP, hereinafter also referred to as the A?x-37 peptides. It further provides hybridoma cells producing the monoclonal antibodies as well as methods for producing the antibodies and the hybridoma cells; and an immunoassay for an A?x-37 peptide by a competitive method or a sandwich method using the antibody of the present invention; and methods for measuring the level of A?x-37 peptides in a sample, such as a biological sample.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: December 16, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Marc Hubert Mercken, Marianne Borgers, Marc Maria Pierre Pelagie Vandermeeren, Bianca Julia J Van Broeck
  • Patent number: 8906649
    Abstract: The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: December 9, 2014
    Assignee: Janssen Biotech, Inc.
    Inventors: John Kehoe, Tatiana Ort, Kristen Picha, Mary Ryan, John Wheeler, Jennifer Lee Gardiner
  • Publication number: 20140356907
    Abstract: A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge.
    Type: Application
    Filed: March 14, 2014
    Publication date: December 4, 2014
    Applicant: ERASMUS UNIVERSITY MEDICAL CENTER
    Inventors: FRANKLIN GERARDUS GROSVELD, RICHARD WILHELM JANSSENS, MARINUS JOHANNES VAN HAPEREN, ROGER KINGDON CRAIG, ERNIE DE BOER
  • Patent number: 8865162
    Abstract: Embodiments of the invention provide methods, monoclonal antibodies, polyclonal antibodies, assays, and kits for detecting HPV infection and HPV related cancer diagnosis, including infection by various HPV genotypes, early and/or late stage HPV-associated or HPV-specific cancers. Various monoclonal antibodies recognizing specific epitope for specific HPV protein or HPV type, common epitope for various HPV proteins or HPV types are obtained. These obtained monoclonal antibodies are useful tools in early clinical detection of HPV infection and general detection of HPV related diseases, specific detection of invasive cervical cancer, detection of other HPV related cancers, early stage precancerous lesions as well as late stage cancer progression.
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: October 21, 2014
    Assignee: OncoHealth Corp.
    Inventor: Shuling Cheng
  • Patent number: 8865874
    Abstract: The present invention is a compound having a structure represented by the following formula (1): and an antibody to BSH obtained by using the compound as a hapten and using a complex of the hapten and a high-molecular compound as an antigen. By using the present invention, it becomes possible to provide a hapten compound for preparing an antibody recognizing BSH highly sensitively and highly selectively, an antibody to BSH, as well as a kit for measuring BSH and an immunological measuring method having high sensitivity and excellent in quantitative property using the antibody.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: October 21, 2014
    Assignees: Japan Science and Technology Agency, Osaka Prefecture University, Stella Chemifa Corporation
    Inventors: Mitsunori Kirihata, Tomoyuki Asano, Kohki Uehara
  • Patent number: 8865398
    Abstract: An in vitro method that allows detection of hepatitis C by detecting hepatitis C virus (HCV) core protein and antibodies to HCV core protein (anti-core antibodies) in a single assay is provided. Cross-reactivity is eliminated in the method preferably by utilizing short peptides, each of which has an amino acid sequence that corresponds to an immunodominant region of the native core protein but which does not wholly encompass the epitope bound by the antibodies utilized in the method. The method can be used to detect the presence of HCV in a subject, and/or to determine the suitability of donor blood or blood products for transfusion purposes. Also provided are diagnostic kits for carrying out the method and a process for selecting suitable capture peptides and monoclonal antibodies for use in the combination method.
    Type: Grant
    Filed: August 28, 2007
    Date of Patent: October 21, 2014
    Assignee: Abbott Laboratories
    Inventors: Brian C. Rodgers, Graham J. Burch
  • Patent number: 8859234
    Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to nucleic acid molecules, including fusion constructs, having catalytic activity and the use of same in glycosylation engineering of host cells to generate polypeptides with improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: October 14, 2014
    Assignee: Roche GlycArt AG
    Inventors: Pablo Umaña, Peter Bruenker, Claudia Ferrara, Tobias Suter
  • Patent number: 8859278
    Abstract: Certain aspects of the present invention are directed to new fully human fusion partner cell lines called human Karyochi cells, and to methods for making them. Human Karyochi cells are then fused with human antibody-secreting lymphoid cells to make fully human hybridomas called Karyochi-based hybridomas, which likewise secrete fully human monoclonal antibodies. Human Karyochi cells are made by isolating a donor nucleus that is substantially free of cytoplasm from either a first malignant B-lymphocyte cell line or a normal B-lymphocyte, and transferring the donor nucleus into the cytoplasm of a recipient cell from a second T- or B-lymphoid cell line. With time the nuclei synchronize and fuse to form the chimeric Karyochi fusion partner cell line. Nuclear transfer can be accomplished using intra-cytosolic nucleus injection or by impact-induced nucleus administration.
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: October 14, 2014
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Ilya Trakht, Gavreel Kalantarov
  • Patent number: 8859218
    Abstract: Embodiments of the invention provide methods, monoclonal antibodies, polyclonal antibodies, assays, and kits for detecting HPV infection and HPV related cancer diagnosis, including infection by various HPV genotypes, early and/or late stage HPV-associated or HPV-specific cancers. The anti-HPV antibodies are used in performing immunological assays on clinical samples. Various immunological assays and kits for detecting HPV infection, cervical cancer, other HPV related cancers, early stage precancerous lesions as well as late stage cancer progression are also provided.
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: October 14, 2014
    Assignee: OncoHealth Corp.
    Inventor: Shuling Cheng
  • Patent number: 8835188
    Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: September 16, 2014
    Assignee: Presidents and Fellows of Harvard College
    Inventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
  • Patent number: 8835187
    Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: September 16, 2014
    Assignee: Presidents and Fellows of Harvard College
    Inventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
  • Patent number: 8828670
    Abstract: The invention relates to a method for producing monomeric or dimeric proteins or peptides containing internal or external disulfide bonds, comprising the following steps: a) a cell-free lysate, obtainable from eukaryotic cells, is provided, which contains functional microsomal vesicles, b) a nucleic acid coding the protein or peptide and additionally containing a signal sequence is added to the lysate, c) the lysate with the nucleic acid is held for a given time at a temperature in the range from 20 to 35° C., proteins or peptides formed with the nucleic acid being translocated into the microsomal vesicles, d) the microsomal vesicles are then dissolved, and the proteins or peptides obtained thereby are optionally separated from the lysate.
    Type: Grant
    Filed: July 10, 2012
    Date of Patent: September 9, 2014
    Assignee: RiNA Netzwerk RNA Technologien GmbH
    Inventors: Helmut Merk, Wolfgang Stiege, Christine Gless, Michael Gerrits
  • Patent number: 8809017
    Abstract: This invention relates to nucleic acid molecules comprising at least one nucleic acid sequence encoding for a peptide or protein of interest, at least one nucleic acid sequence encoding for a selectable marker, and at least one IRES sequence, wherein the at least one IRES sequence is located between the at least one nucleic acid sequence encoding for the peptide or protein of interest and the at least one nucleic acid sequence encoding for the selectable marker. Furthermore, this invention relates to host cells comprising such nucleic acid molecule and to methods of recombinant protein expression using such host cells.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: August 19, 2014
    Assignee: Agency for Science, Technology and Research
    Inventors: Yuansheng Yang, Steven Ho, Jia Juan Lee